Drug Profile
JNJ 28045446
Alternative Names: JNJ-28045446Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Class
- Mechanism of Action Platelet ADP receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Thrombosis in USA
- 03 Aug 2007 Preclinical trials in Thrombosis in USA (unspecified route)
- 03 Aug 2007 Data presented at the 21st Congress of the International Society on Thrombosis and Haemostasis (ISTH-2007) added to the pharmacokinetics and Thromboses pharmacodynamics sections